1-Methyl-2-methylmercapto-5-phenyl-imidazol | 25433-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-Methyl-2-methylmercapto-5-phenyl-imidazol
• 英文别名: 1-Methyl-2-methylthio-5-phenyl-imidazol；1-methyl-2-methylsulfanyl-5-phenyl-1H-imidazole；1-methyl-2-methylthio-5-phenyl-imidazole；1-methyl-2-(methylthio)-5-phenyl-1H-imidazole；1-methyl-2-methylsulfanyl-5-phenylimidazole
• CAS: 25433-15-2
• 化学式: C₁₁H₁₂N₂S
• mdl: MFCD16633405
• 分子量: 204.296
• InChiKey: LSLHTSZRWOOYPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
  申请人：The Interthyr Corporation

  公开号：EP2399578A1

  公开（公告）日：2011-12-28

  The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with over-expression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The present invention also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. This invention also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with the Toll-like receptor overexpression or signaling.

  本发明涉及治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中Toll样受体3（TLR3）以及Toll样受体4（TLR4）和/或TLR3/TLR4信号过度表达有关的自身免疫性和/或炎症性疾病，以及相关病理。本发明还涉及苯基甲巯咪唑、甲巯咪唑衍生物和同分异构环硫代甲烷用于治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中的Toll样受体3（TLR3）以及Toll样受体4（TLR4）和/或TLR3/TLR4信号转导相关的自身免疫性和炎症性疾病。本发明还涉及治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中 Toll 样受体 3 以及 Toll 样受体 4 和/或 TLR3/TLR4 信号异常有关的疾病或病症。本发明还涉及治疗与 TLR 过度表达和信号转导相关的自身免疫炎症性病症以及趋化因子和细胞因子介导的疾病。本发明还涉及能够抑制与 Toll 样受体过度表达或信号转导相关的 IRF-3/1型 IFN/STAT/ISRE/IRF-1 通路的药物制剂。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER
  申请人：Kohn Leonard D.

  公开号：US20100004304A1

  公开（公告）日：2010-01-07

  It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the activation of STAT, a key regulator of cancer growth, survival, metastasis, immune evasion and angiogenesis. Increased IL-6 and Stat-3 exists in vitro in pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells with high basal expression of Toll-like receptor 3 (TLR3) and Wnt5a. IL6/STAT3 activation, mediated by overexpressed TLR3 signaling, appears important in the tumor growth process, it may increase Wnt5a signaling, and be associated with increased cellular growth and migration. Using a novel inhibitor of pathologic TLR3 signaling (5-phenylmethimazole [C10]) we have demonstrated decreases in these markers plus suppression of cell growth and migration in human pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells.
• Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
  申请人：Kohn Leonard D.

  公开号：US20120238610A1

  公开（公告）日：2012-09-20

  Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.
• USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION
  申请人：Ohio University

  公开号：US20160220536A1

  公开（公告）日：2016-08-04

  Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.
• US6365616B1
  申请人：——

  公开号：US6365616B1

  公开（公告）日：2002-04-02